Close menu




September 14th, 2021 | 13:07 CEST

Nvidia, BrainChip Holdings, Palantir - To the moon

  • Technology
Photo credits: pixabay.com

According to high-ranking managers of the largest chip manufacturers such as Intel and Nvidia, the end of the semiconductor crisis is not in sight before the end of 2022. Besides the increasing demand for consumer electronics, computers and accessories since the beginning of the Corona Crisis, the industry is also being hit by the strong growth in demand from the automotive industry, which is increasingly relying on electronics. Artificial intelligence, 5G and the Internet of Things will further fuel demand in the coming years.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: NVIDIA CORP. DL-_001 | US67066G1040 , BRAINCHIP HOLDINGS LTD | AU000000BRN8 , PALANTIR TECHNOLOGIES INC | US69608A1088

Table of contents:


    BrainChip Holdings - Welcome to the revolution

    As early as 1950, Alan Turing first posed the question of whether machines could think. Since then, tremendous progress has been made in the field of artificial intelligence. Today, artificial intelligence is transforming both society and business. AI enables productivity gains, can improve quality of life, and even help address global challenges such as climate change, resource scarcity, and health crises.

    However, one of the biggest problems with today's AI systems is their high power consumption. Unlike general-purpose chips like the familiar CPUs that need to communicate regularly with the data center, wasting vast amounts of precious energy, Australian Company BrainChip Holdings developed Akida. This revolutionary event-based processor works in the same way as the human brain, meaning it processes so-called spikes instead of traditional computer data.

    The Akida processor can learn independently and does most of its work on-chip rather than in the data center, significantly reducing Internet bandwidth and latency. As a result, Akida meets the requirements of modern edge devices and is expected to be used in autonomous driving, IoT devices, robotics, medical diagnostics and security. The pattern was developed in collaboration with SocioNext, a leading application-specific integrated circuit company. Manufactured by Taiwan Semiconductor, the first generation was shipped last month. So it should be a matter of time before the big names in both the semiconductor and electrical industries take notice of the world first.

    In 2019, chip giant Intel bought Israeli developer of programmable deep learning accelerators designed for the data center, Habana Labs, for USD 2 billion. Analysts at Pitt Street Research take this acquisition as a peer group comparison and therefore see a fair value of AUD 1.50, equivalent to EUR 0.94, for BrainChip Holdings' stock. The current share price in Frankfurt is EUR 0.32, which, according to the experts, represents a 200% opportunity.

    Nvidia - Unstoppable

    Quarter after quarter, the market leader of chip producers, Nvidia, proves its supremacy. Especially in the gaming segment, the Company has set a gold standard. The business with gamers contributes more than 40% of the total revenue. Besides the gaming sector, Nvidia is also successful in AI, data centers and automotive.

    The strategically smart merger with ARM could lift the stock to completely new valuation levels in the future. ARM supplies IP technologies to semiconductor manufacturers and central processing units around the world. The suppliers use the intellectual property to produce semiconductor chips for their products and applications. According to insiders, the US Company plans to submit an application to the European Commission for the USD 54 billion acquisition of British chip developer ARM later in September. The Reuters news agency reported that the antitrust regulator is expected to begin an investigation that will last several months. The deadline for the acquisition is March, so the elephant wedding could be close. Initial criticism has already emerged from British antitrust watchdogs that the deal could harm competition.

    Nvidia's share price has increased more than fivefold since the beginning of 2020 and is trading at USD 228, close to its all-time high of USD 230. Another breakout would generate a price target of USD 260. However, the stock is slowly entering overbought territory, so investors should set stop-loss orders. If the planned transaction with ARM is canceled, major setbacks loom.

    Palantir - Cooperation terminated

    Criticism from data privacy campaigners over a lack of transparency in contract awards to the US data giant prompted the UK's Department of Health to terminate an existing contract with Palantir. In August, the Department of Health and Social Care had issued a tender to move its Adult Social Care Dashboard from third-party vendors to an in-house system built by BAE Systems Plc, Europe's largest defense contractor. The successor is UK-based IT consultancy Mozaic Services, which already serves clients like Aviva, BP and the UK's National Health Service.

    For the Palo Alto-based data analytics company, the loss of the relatively small contract is something to get over. From a technical perspective, prices around the USD 25 support area offer good long-term entry opportunities.


    The chip shortage will continue to accompany us into the near future. New systems are more likely to increase demand. BrainChip Holdings developed a revolutionary chip that works like the human brain and offers significant advantages over competing products. Nvidia is the benchmark in the semiconductor industry, but at current levels, the air to the top is getting thinner. In contrast, Palantir offers a long-term buying opportunity.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read